PHARMACHON: Pharmacokinetics of VOXZOGO
The following, written by Victoria Garcia, RN, exclusively for The Chandler Project and members of the achondroplasia community are questions and answers compiled from ‘One Family’s Story: A Guide to…
PHARMACHON • JUNE 16-18 • CHICAGO, IL
The following, written by Victoria Garcia, RN, exclusively for The Chandler Project and members of the achondroplasia community are questions and answers compiled from ‘One Family’s Story: A Guide to…
Life-changing breakthrough for children Murdoch Children’s Research Institute (MCRI) recently shared a new article from the Herald Sun titled ‘New Drug Treats Dwarfism’ written by Sue Dunlevy. In the post,…
The Supplemental New Drug Application is Based on Positive Results from Global Randomized Phase 2 Study in Infants and Young Children FDA set PDUFA Target Action Date of October 21, 2023…
Did you know that more than 90% of rare diseases are still without an FDA-approved treatment? On November 19, 2021, the U.S. Food and Drug Administration approved the first drug to improve growth in…
BioMarin Submits Supplemental New Drug Application to U.S. Food and Drug Administration to Expand Label to Treat Children with Achondroplasia Under the Age of 5 Submissions Based on Favorable Results…
SAN RAFAEL, Calif., Nov. 19, 2021 /PRNewswire/ — BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to VOXZOGO™ (vosoritide) for Injection, indicated…